Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Features

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Shelley Wood

December 30, 2016

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Features

Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más

Shelley Wood

December 30, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular News and Features for 2016

Shelley Wood

December 29, 2016

News Opinion Editor's Corner

TCTMD 年十大热门新闻、博客和焦点

Shelley Wood

December 29, 2016

News Opinion Editor's Corner

Las Noticias y Blogs Más Populares de TCTMD en 2016

Shelley Wood

December 29, 2016

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2016

Caitlin E. Cox

September 01, 2016

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Daily News

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Todd Neale

August 01, 2016

News Conference News TVT 2016

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

Michael O'Riordan

June 16, 2016

News Conference News EuroPCR 2016

Valvular Interventions for the Asymptomatic and Low Risk: Coming Soon to a Cath Lab Near You?

Yael L. Maxwell

May 20, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2016

Shelley Wood

April 29, 2016

News Daily News

For Inoperable Patients, TAVR Carries Benefits but Raises Lifetime Costs

July 25, 2013

News Daily News

En Pacientes Inoperables, la TAVR produce Beneficios pero Dispara el Gasto de por Vida

July 25, 2013

News Daily News

FDA, CMS Parallel Review Aims to Speed Access to Innovative Technologies

L.A. McKeown

October 14, 2011

News Conference News

PARTNER: TAVI Cost Effective Compared With Standard Care

Jason Kahn

April 03, 2011

Advertisement

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más

TCTMD’s Top 10 Most Popular News and Features for 2016

TCTMD 年十大热门新闻、博客和焦点

Las Noticias y Blogs Más Populares de TCTMD en 2016

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

TCTMD’s Top 10 Most Popular Stories for August 2016

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

Valvular Interventions for the Asymptomatic and Low Risk: Coming Soon to a Cath Lab Near You?

TCTMD’s Top 10 Most Popular Stories for April 2016

For Inoperable Patients, TAVR Carries Benefits but Raises Lifetime Costs

En Pacientes Inoperables, la TAVR produce Beneficios pero Dispara el Gasto de por Vida

FDA, CMS Parallel Review Aims to Speed Access to Innovative Technologies

PARTNER: TAVI Cost Effective Compared With Standard Care

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content